Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dendreon’s Story Of Continuing Slow Growth For Provenge Seems Unconvincing To Wall Street

This article was originally published in The Pink Sheet Daily

Executive Summary

Dendreon’s new CEO has yet to articulate whether he plans large-scale strategic changes to how the company markets Provenge, instead focusing his early comments to investors on deeper penetration of existing accounts and guiding to low-single-digit quarterly sales growth.

Advertisement

Related Content

Opening A Window: Algeta Must Find Xofigo’s Place In The Prostate Cancer Market
A New Chapter, A New CEO For Dendreon
Dendreon Rebounds In Q4 2011, But Can It Keep It Up In 2012?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074219

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel